AG真人官方

Owlet Reports Second Quarter 2025 Financial Results; Increases Full Year 2025 Guidance; Announces CEO Transition Plan

LEHI, Utah--(BUSINESS WIRE)-- Owlet, Inc. (鈥淥wlet鈥� or the 鈥淐ompany鈥�) (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the second quarter ended June 30, 2025. Owlet鈥檚 Chief Executive Officer and Co-Founder, Kurt Workman; President, Jonathan Harris; and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company鈥檚 results and provide a business and corporate update today, August 7, 2025, at 4:30 p.m. ET.

Q2 2025 Financial Highlights

• Q2 Revenue of $26.1 million, up 25.9% from Q2 2024
• Q2 Gross Margin of 51.3%, up 180 basis points from Q2 2024
• Q2 Net Loss of $37.6 million, including a $34.8 million non-cash, mark-to-market common stock warrant liability adjustment, compared to net loss of $1.1 million in Q2 2024
• Q2 Adjusted EBITDA of $0.3 million, improving $0.2 million compared to Q2 2024

鈥淥ur exceptional team continues to execute at a high level as Q2 outperformed expectations across all key metrics,鈥� said Kurt Workman, Owlet鈥檚 Chief Executive Officer and Co-Founder. 鈥淲e drove strong revenue of $26.1 million in the quarter, growing 26% year-over-year, contributing to our largest first half revenue performance in Company history. We also delivered another quarter of year-over-year gross margin expansion and adjusted EBITDA improvement, reflecting the healthy momentum in the business.鈥�

Workman continued, 鈥淥ur Owlet360 subscription continues to trend positively, recently surpassing 66,000 paying subscribers with steady growth in monthly recurring revenue, attach rate, retention rate, and consumer satisfaction. With the ongoing growth in our core business, and the exciting momentum in Owlet360 subscription, we believe Owlet is uniquely positioned to capture the addressable market opportunities in pediatric health, as we continue our evolution from a hardware company into a comprehensive pediatric health platform.鈥�

CEO Transition Effective October 1, 2025

Owlet today also announced that Jonathan Harris, Owlet鈥檚 current President, will succeed Kurt Workman as Chief Executive Officer, effective October 1, 2025, and Mr. Workman will transition to Executive Chairman of the Board of Directors.

鈥淚 founded Owlet over 12 years ago because I believe that every baby should have access to medical-grade health monitors at home, and we鈥檝e never been closer to that vision,鈥� said Mr. Workman. 鈥淭his organizational change will allow me to focus more deeply on the things I鈥檓 most passionate about鈥攅xpanding access to Owlet鈥檚 mission and helping guide the Company鈥檚 long-term strategy as we continue to grow.鈥�

Mr. Workman continued, 鈥淥wlet could not have a better CEO going forward. Jonathan is an extremely accomplished executive with a proven ability to consistently deliver value to a full range of stakeholders. Jonathan鈥檚 leadership and commitment to Owlet鈥檚 mission has already made an incredible impact on the company over the past two years with him leading our global go-to-market directly following FDA and CE mark clearances, spearheading international growth and distribution, standing up our Owlet360 subscription offering, and driving a more focused, streamlined organization. Undoubtedly, the momentum and performance we鈥檝e delivered in recent quarters are a direct result of Jonathan鈥檚 impact on the business and his valuable leadership. Jonathan has been pivotal in the transformation of Owlet as a comprehensive pediatric health platform, and he is ideally suited to lead as Owlet鈥檚 CEO through this next phase of growth.鈥�

Financial Results for the Second Quarter Ended June 30, 2025

Revenue for the second quarter of 2025 was $26.1 million compared to revenue in the second quarter of 2024 of $20.7 million, an increase of 25.9%. The increase was primarily due to higher sales of Dream Sock and Dream Duo products.

Cost of revenue for the second quarter of 2025 was $12.7 million with a gross margin of 51.3%, compared to cost of revenue of $10.4 million with a gross margin of 49.5% for the second quarter of 2024. Gross margin increased 180 basis points year-over-year, primarily due to higher revenue, favorable product mix toward Dream Sock, lower direct product and fulfillment costs, and fixed cost absorption, partially offset by the impact of tariffs.

Operating expenses, including stock-based compensation, were $15.3 million for the second quarter of 2025, compared to $12.5 million for the same period in 2024. Operating costs increased year-over-year primarily due to higher compensation expense, including accrued bonuses.

Operating loss was $1.9 million for the second quarter of 2025, compared to operating loss of $2.2 million for the second quarter of 2024.

Net loss was $37.6 million for the second quarter of 2025, including a $34.8 million common stock warrant liability mark-to-market adjustment, compared to net loss of $1.1 million for the second quarter of 2024.

Adjusted EBITDA was $0.3 million for the second quarter of 2025, compared to a $0.1 million for the second quarter of 2024, an improvement of $0.2 million.

Net loss per share was $2.37 for the second quarter of 2025, compared to net loss per share of $0.30 for the second quarter of 2024. Adjusted net loss per share was $0.05 for the second quarter of 2025, compared to adjusted net income per share of $0.00 for the same period in 2024.

Updated 2025 Financial Outlook

For the full year 2025, we now expect revenue in the range of $97 million to $100 million, or 24% to 28% growth year-over-year, gross margins in the range of 46% to 50% including the impact of new expected tariff costs, and we now fully expect to be adjusted EBITDA profitable for full year 2025.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 鈥淩eform Act鈥�). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company鈥檚 expected financial performance, including the Company鈥檚 financial outlook, outlook based upon regulatory authorizations or product enhancements, growth prospects, future operational efficiencies or results, expected market opportunity and acceptance, and changes in senior management. In some cases, you can identify forward-looking statements by terms such as 鈥渆stimate,鈥� 鈥渕ay,鈥� 鈥渂elieves,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥済oal,鈥� 鈥減otential,鈥� 鈥渦pcoming,鈥� 鈥渙utlook,鈥� 鈥済uidance,鈥� the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company鈥檚 expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company鈥檚 actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company鈥檚 future results and cause those results to differ materially from those expressed in or implied by the Company鈥檚 forward-looking statements. Such factors include, but are not limited to, (i) the regulatory pathway for Owlet鈥檚 products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet鈥檚 ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (ii) Owlet鈥檚 competition and the Company鈥檚 ability to profitably grow and manage growth; (iii) the Company鈥檚 ability to enhance future operating and financial results or obtain additional financing to continue as a going concern; (iv) Owlet鈥檚 ability to obtain additional financing in the future, as well risks associated with the Company鈥檚 current loan and debt agreements, including compliance with debt covenants, restrictions on the Company鈥檚 access to capital, the impact of the Company鈥檚 overall debt levels and the Company鈥檚 ability to generate sufficient future cash flows to meet Owlet鈥檚 debt service obligations and operate Owlet鈥檚 business; (v) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vi) Owlet鈥檚 ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements, including but not limited to requirements concerning privacy and data protection, breaches and loss, as well as other risks associated with Owlet鈥檚 digital platforms and technologies; (vii) Owlet鈥檚 ability to maintain relationships with customers, manufacturers and suppliers and retain Owlet鈥檚 management and key employees; (viii) Owlet鈥檚 ability to upgrade and maintain its information technology systems; (ix) changes in applicable laws or regulations in the United States and other jurisdictions; (x) the impact of and disruption to Owlet鈥檚 business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company鈥檚 control, such as health epidemics or pandemics, macro-economic uncertainties, tariffs or trade restrictions, social unrest, hostilities, natural disasters or other catastrophic events; (xi) the possibility that Owlet may be adversely affected by other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xii) other risks and uncertainties set forth in the Company鈥檚 other releases, public statements and filings with the U.S. Securities and Exchange Commission (鈥淪EC鈥�), including those identified in the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated in the Company鈥檚 quarterly reports on Form 10-Q, as any such factors may be updated from time to time in the Company鈥檚 other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company鈥檚 behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.

Disclosure Regarding Non-GAAP Financial Measures

In addition to the financial measures presented in this release in accordance with U.S. Generally Accepted Accounting Principles (鈥淕AAP鈥�), the Company has included certain non-GAAP financial measures in this release, including EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share.

The Company uses such non-GAAP financial measures as internal measures of business operating performance and as performance measures for benchmarking against the Company鈥檚 peers and competitors. The Company believes its presentation of EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share provides a meaningful perspective of the underlying operating performance of the Company鈥檚 current business and enables investors to better understand and evaluate its historical and prospective operating performance. The Company believes that these non-GAAP financial measures are important supplemental measures of operating performance because they exclude items that vary from period to period without correlation to the Company鈥檚 core operating performance and highlight trends in its business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of the Company鈥檚 future operating performance. The Company believes investors, analysts and other interested parties use EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of the Company鈥檚 operating performance in addition to the Company鈥檚 performance based on GAAP results.

The Company鈥檚 non-GAAP financial measures should not be considered as an alternative to net income (loss) or net income (loss) per share as a measure of financial performance or any other performance measure derived in accordance with GAAP and should not be construed as an inference that the Company鈥檚 future results will be unaffected by unusual or non-recurring items.

EBITDA is defined as net income (loss) adjusted for income tax provision, interest expense, net, depreciation and amortization, and impairment of intangible assets.

Adjusted EBITDA is defined as net income (loss) adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustments, stock-based compensation, transaction costs, and charges related to certain legal matters.

Adjusted net income (loss) is defined as net income (loss) adjusted for common stock warrant liability adjustments, stock-based compensation, transaction costs, impairment of intangible assets, and charges related to certain legal matters. Adjusted net income (loss) per share is defined as adjusted net income (loss) divided by the basic weighted-average number of shares of common stock outstanding.

EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share are not recognized terms under GAAP, and the Company鈥檚 presentation of these non-GAAP measures does not replace the presentation of the Company鈥檚 financial results in accordance with GAAP. Because all companies do not use EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way the Company calculates such measures. The non-GAAP financial measures included in this release should not be construed as substitutes for or better indicators of the Company鈥檚 performance than the most directly comparable GAAP financial measures. See the reconciliation tables that accompany this release for additional information regarding certain of the non-GAAP financial measures included herein.

A reconciliation of the Company's guidance with respect to non-GAAP financial measures to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, the amounts of which could be material.

Conference Call and Webcast Information

Owlet will host a conference call and webcast today, August 7, 2025, at 4:30 p.m. ET to discuss these results and provide a business and corporate update.

Participants may access the call at 833-470-1428 (domestic) or 404-975-4839 (international) and reference Access Code 579904. A simultaneous webcast may be accessed online at the Events section of Owlet鈥檚 Investor Relations website at . A replay will be available shortly after the webcast concludes.

About Owlet, Inc.

Owlet鈥檚 digital health infant monitoring platform is transforming the journey of parenting. Owlet, Inc. (NYSE:OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.

Since 2012, over 2 million parents worldwide have used Owlet鈥檚 platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.

To learn more, visit .

听

View source version on businesswire.com:

Investor Relations: [email protected]

Media: [email protected]

Source: Owlet, Inc.